Improving contract processing capacity
First written in FY2019. 17 of 26 entries say "Advanced", first in FY2020-Q1. Latest entry: 2026-09-09.
No other company in this theme has enough history to compare yet.
- 2026-09-09Advancednews.livedoor.com
「CellSource rebounds sharply as contract processing services exceed expectations and FY October 2026 revenue and operating profit forecasts are raised」
Contract processing services exceeded expectations, and the sales and operating profit forecasts for the fiscal year ending October 2026 were reportedly revised upward. - FY2026-H1Decline in Contract Processing OrdersAnnual report
「Meanwhile, the number of contract processing cases per medical institution remained sluggish, and the total number of contract processing cases for blood-derived processing services and adipose-derived stem cell processing services declined from 10,303 in the previous interim consolidated accounting period to 10,114 in the current interim consolidated accounting period.」
Although the number of affiliated medical institutions increased, the number of contract processing cases per medical institution remained sluggish, and the number of contract processing cases decreased by 189 year on year. - 2026-05-14OtherMonthly
「The average number of outsourced processing orders per day in April was 56.5, slightly below the same month of the previous year.」
The average number of outsourced processing orders per day was below the same month of the previous year. By contrast, orders for the hybrid orthopedic model increased year on year to a record-high level. - FY2025Decline in Contract Processing OrdersAnnual report
「During the consolidated fiscal year, we expanded our manufacturing sites to improve processing capacity in line with the increase in contract processing cases. Going forward, the Group will further promote the use of highly skilled personnel with specialized knowledge, improve the efficiency of work processes by consolidating sites and improving processing operations, and enhance the efficiency and capacity of contract processing through technological development and other measures.」
Even after the expansion of manufacturing sites, the number of contract processing cases decreased by 2,112 from 22,944 in the previous fiscal year to 20,832. The company indicated a policy of improving processing capacity through site consolidation, process improvements, technological development and the use of human resources. - FY2025-H1Decline in Contract Processing OrdersAnnual report
「Meanwhile, the number of contract processing cases per medical institution remained sluggish, and the total number of contract processing cases for blood-derived processing services and adipose-derived stem cell processing services declined from 11,255 in the same period of the previous year to 10,303 in the current six-month consolidated accounting period.」
Although the number of affiliated medical institutions increased, the number of contract processing cases per medical institution remained sluggish, and the number of contract processing cases fell by 952 year on year to 10,303. - FY2024-Q2Decline in Contract Processing OrdersAnnual report
「The total number of contract processing cases for blood-derived processing services and adipose-derived stem cell processing services was 11,255 in the cumulative second quarter, compared with 13,398 in the same period of the previous year.」
The number of contract processing cases decreased by 2,143 year on year, reaching 5,570 in the quarter compared with 5,685 in the immediately preceding quarter. - FY2024-Q1Decline in Contract Processing OrdersAnnual report
「The total number of contract processing cases for blood-derived processing services and adipose-derived stem cell processing services was 5,685 in the cumulative first quarter, compared with 6,520 in the same period of the previous year.」
The number of contract processing cases decreased by 835 year on year. No new progress in enhancing manufacturing-site capacity was reported during the quarter. - FY2023AdvancedAnnual report
「During the fiscal year, we expanded our manufacturing sites through rational investment.」
We expanded our manufacturing sites and opened Haneda Global CPC in Tonomachi, Kawasaki, Kanagawa Prefecture, in August 2023. Capacity expansion to accommodate the increase in contract processing volumes progressed to the specific equipment phase. - FY2023-Q3AdvancedAnnual report
「As a result, the combined number of contract processing orders for blood-derived processing services and adipose-derived stem cell processing services increased from 16,091 in the same period of the previous year to 20,584 in the cumulative third quarter, and net sales from contract processing services and consulting services grew.」
The number of contract processing orders increased by 4,493, from 16,091 in the same period of the previous year to 20,584. Net sales from contract processing services in the third quarter were ¥873.909 million. - FY2023-Q2AdvancedAnnual report
「With the acquisition of the new CPC (cell processing center) this time, we will expand the manufacturing site area by more than 10-fold and strengthen our manufacturing capabilities in anticipation of increased future contract orders and the launch of new businesses, including the exosome drug discovery business.」
To address growing demand, the Company decided to establish a new CPC in Tonomachi, Kawasaki, Kanagawa Prefecture. The planned capital investment is ¥50.0 million, with operations scheduled to begin in or after November 2023, and the manufacturing site area will be expanded by more than 10 times. - FY2023-Q1AdvancedAnnual report
「As a result, the combined number of contract processing orders for blood-derived processing services and adipose-derived stem cell processing services increased from 4,488 in the same period of the previous year to 6,520 in the cumulative first quarter, and net sales from contract processing services and consulting services grew.」
The number of contract processing orders increased by 2,032, from 4,488 in the same period of the previous year to 6,520. However, due to seasonal factors, the number declined from 7,071 in the immediately preceding quarter to 6,520. - FY2022AdvancedAnnual report
「The combined number of contract processing orders for blood-derived processing services and adipose-derived stem cell processing services increased from 15,142 in the previous fiscal year to 23,162 in the current fiscal year.」
The number of contract processing orders increased by 8,020, from 15,142 to 23,162. Total capital investment was ¥102.569 million, of which the principal item was ¥84.2 million for expanding CPC manufacturing facilities. - FY2022-Q3AdvancedAnnual report
「Number of contract processing orders 4,091 4,294 4,488 4,711 6,892 +2,181」
The number of contract processing orders increased by 2,181, from 4,711 in the previous quarter to 6,892, representing a substantial expansion in the volume of contract processing. - FY2022-Q2AdvancedAnnual report
「Number of contract processing orders 3,690 4,091 4,294 4,488 4,711 +223」
The number of contract processing orders increased by 223, from 4,488 in the previous quarter to 4,711, and the volume of contract processing continued to expand. - FY2022-Q1AdvancedAnnual report
「Number of contract processing orders 3,067 3,690 4,091 4,294 4,488 +194」
The number of contract processing orders increased by 194, from 4,294 in the previous quarter to 4,488, and the volume of contract processing continued to expand. - FY2021AdvancedAnnual report
「The number of contract processing orders increased from 8,056 in the previous fiscal year to 15,142 in the current fiscal year, and net sales from contract processing services and consulting services grew steadily.」
The number of contract processing orders increased by 7,086, from 8,056 to 15,142. The Company invested ¥30.278 million in expanding CPC manufacturing facilities and continued to outsource some processing and improve process efficiency. - FY2021-Q3AdvancedAnnual report
「Number of contract processing orders 2,046 2,529 3,067 3,690 4,091 +401」
The number of contract processing orders increased by 401, from 3,690 in the previous quarter to 4,091, and the volume of contract processing continued to expand. - FY2021-Q2AdvancedAnnual report
「Number of contract processing orders 1,559 2,046 2,529 3,067 3,690 +623」
The number of contract processing orders increased by 623, from 3,067 in the immediately preceding quarter to 3,690, and the volume of contract processing continued to expand. - FY2021-Q1AdvancedAnnual report
「Number of contract processing orders 1,922 3,067 +1,145」
The number of contract processing orders increased by 1,145, from 1,922 in the same period of the previous year to 3,067, and the volume of contract processing continued to expand. - FY2020AdvancedAnnual report
「The number of contract processing orders, on an order basis, increased steadily to 8,056 in the current fiscal year from 5,228 in the previous fiscal year, and the Company expects this trend to continue. To increase processing capacity in line with the growth in contract processing orders, the Company is working to improve process efficiency by upgrading and expanding the media, equipment, and other items used in processing operations, partially outsourcing processing operations to external providers, and recruiting and training highly capable personnel with specialized knowledge and skills.」
The number of contract processing orders increased by 2,828, from 5,228 to 8,056. Measures to increase processing capacity, including the expansion of CPC manufacturing facilities, were also implemented. - FY2020-Q3AdvancedAnnual report
「As a result, the combined number of contract processing orders for adipose-derived stem cell processing services and blood-derived processing services in the cumulative third quarter was 5,527, up 2,115 from the same period of the previous year. Net sales from contract processing services, consulting services, and medical equipment sales all grew steadily.」
The cumulative third-quarter number of contract processing orders was 5,527, up 2,115 from the same period of the previous year. The number in the third-quarter accounting period recovered to 2,046. - FY2020-Q2AdvancedAnnual report
「As a result, the combined number of contract processing orders for adipose-derived stem cell processing services and blood-derived processing services in the cumulative second quarter was 3,481, up 1,693 from the same period of the previous year. Net sales from contract processing services, consulting services, and medical equipment sales all grew steadily. Contract processing services were affected by the nationwide spread of COVID-19, with orders declining from 1,922 in the first-quarter accounting period (November to January) to 1,559 in the second-quarter accounting period (February to April).」
The cumulative second-quarter number of contract processing orders was 3,481, up 1,693 from the same period of the previous year, while the number in the second-quarter accounting period declined to 1,559 due to the impact of COVID-19. - FY2020-Q1AdvancedAnnual report
「Utilization of the contract services by partner medical institutions has also increased, partly in response to effective treatment outcomes. As a result, the combined number of contract processing orders for adipose-derived stem cell processing services and blood-derived processing services in the cumulative first quarter was 1,922, up 1,057 from the same period of the previous year. Net sales from contract processing services, consulting services, and medical equipment sales all grew steadily.」
The Company reported increased utilization of its contract services and 1,922 contract processing orders, up 1,057 from the same period of the previous year. - FY2019First statedAnnual report
「The number of contract processing orders, on an order basis, increased steadily to 5,228 in the current fiscal year from 2,320 in the previous fiscal year, and the Company expects this trend to continue. To increase processing capacity in line with the growth in contract processing orders, the Company is working to improve process efficiency by upgrading and expanding the media, equipment, and other items used in processing operations, as well as recruiting and training highly capable personnel with specialized knowledge and skills.」
To accommodate the increase in contract orders, the Company plans to upgrade and expand equipment, improve process efficiency, recruit and train personnel, and outsource part of the processing to external providers.